Foghorn Therapeutics
FHTX
61 hedge funds and large institutions have $379M invested in Foghorn Therapeutics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 22 reducing their positions, and 11 closing their positions.
2% more funds holding
Funds holding: 60 → 61 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
5.18% less ownership
Funds ownership: 65.31% → 60.13% (-5.2%)
23% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 22
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
32% less capital invested
Capital invested by funds: $554M → $379M (-$174M)
98% less call options, than puts
Call options by funds: $3K | Put options by funds: $196K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.76M |
| 2 |
Morgan Stanley
New York
|
+$6.54M |
| 3 |
DM
Deerfield Management
New York
|
+$3.28M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.16M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$904K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$5.49M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.19M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$3.41M |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$2.36M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$1.43M |
FHTX Hedge Fund Activity: Q1 2022 in Review
61 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q1 2022, worth a combined $379M — down 32% from $554M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new FHTX positions and 11 closed out — a net gain of 1 holder — while 17 added to existing stakes and 22 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $9.76M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $5.49M sold.
- 61 institutional investors held Foghorn Therapeutics (FHTX) as of Q1 2022, up from 60 in Q4 2021.
- Funds reported $379M of Foghorn Therapeutics stock for Q1 2022, down 32% quarter-over-quarter.
- 12 funds opened new Foghorn Therapeutics positions in Q1 2022 and 11 closed out, a net change of +1 holder.
- The largest Foghorn Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $9.76M added.
- The largest Foghorn Therapeutics seller in Q1 2022 was Monashee Investment Management, an estimated $5.49M sold.
Based on aggregated 13F filings for Q1 2022.